STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #975 by analyst upside · 2026-08-13
TLX
Telix Pharmaceuticals Limited
Healthcare · Market Cap $4B · P/E 0x
ANALYST PRICE TARGET
+76.3%
implied upside to consensus target
Current Price $11.97
Consensus Target $21.1
Bull Target $22.27
Bear Target $19.72
Analysts Covering 4
ANALYST CONSENSUS - BUY
Strong Buy
0
Buy
4
Hold
0
Sell
0
52-Week Low $6.28
52-Week High $12.6
YTD Return +57.1%
FUNDAMENTALS
Market Cap $4B
P/E Ratio (TTM) N/A
Forward P/E 65.4x
EPS (TTM) $-0.02
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $804M
Profit Margin -0.9%
52-WEEK RANGE
52-Week Low $6.28
52-Week High $12.6
Current Price $11.97
Bear Target $19.72
Bull Target $22.27
● Now $11.97 ● Target $21.1
TRADING DATA
Avg Volume 159K
YTD Return +57.1%
Analyst Count 4
Consensus Buy
Upside to Target +76.3%
Last Updated 2026-08-13

ANALYST SUMMARY

Telix Pharmaceuticals Limited (TLX) is currently trading at $11.97 with a Wall Street consensus price target of $21.1, implying potential upside of 76.3% over the next 12 months. 4 analysts currently cover TLX, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $22.27, while the most cautious has a target of $19.72.

TLX operates in the Healthcare sector with a market capitalisation of $4B. The stock is up 57.1% year-to-date and is currently trading near the upper end of its 52-week range of $6.28 – $12.6.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for TLX, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Wedbush reit
Outperform → Outperform 2026-04-13 Building track record
HC Wainwright & Co. reit
Buy → Buy 2026-04-13 31% win rate (48 calls)
Wedbush reit
Outperform → Outperform 2026-04-07 Building track record
HC Wainwright & Co. reit
Buy → Buy 2026-04-07 31% win rate (48 calls)
Citigroup - Reiterated
Buy → Buy 2026-02-24 Building track record
HC Wainwright & Co. reit
Buy → Buy 2026-01-21 31% win rate (48 calls)
HC Wainwright & Co. reit
Buy → Buy 2025-12-22 31% win rate (48 calls)
UBS - Reiterated
Buy → Buy 2025-09-23 33% win rate (6 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
65
out of 100
Coverage depth
12/30
Consensus clarity
26/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →